Making Sense of Multifunctional Proteins: Human Immunodeficiency Virus Type 1 Accessory and Regulatory Proteins and Connections to Transcription

Annual Review of Virology

Volumn 4, Issue , 2017, Pages 241-260

  Faust, Tyler B ^a   Binning, Jennifer M ^b   Gross, John D ^b   Frankel, Alan D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Host pathogen interactions; Human immunodeficiency virus; Multifunctional proteins; Transcription; Virus replication

Indexed keywords

NEF PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; VIF PROTEIN; VPR PROTEIN; VPU PROTEIN; HUMAN IMMUNODEFICIENCY VIRUS PROTEIN; VIRAL PROTEIN; VPU PROTEIN, HUMAN IMMUNODEFICIENCY VIRUS 1;

ARTICLE; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; VIRUS TRANSCRIPTION; CHEMISTRY; GENETIC TRANSCRIPTION; GENETICS; HOST PATHOGEN INTERACTION; HUMAN; METABOLISM; PHYSIOLOGY; REGULATOR GENE; VIRUS REPLICATION;

GENES, REV; GENES, TAT; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMAN IMMUNODEFICIENCY VIRUS PROTEINS; HUMANS; NEF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION, GENETIC; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRAL REGULATORY AND ACCESSORY PROTEINS; VIRUS REPLICATION; VPR GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS;

EID: 85030323086     PISSN: 2327056X     EISSN: 23270578     Source Type: Journal    
DOI: 10.1146/annurev-virology-101416-041654     Document Type: Article

References (152)

1. Worobey M, Gemmel M, Teuwen DE, Haselkorn T, Kunstman K, et al. 2008. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 455:661-64
2. Chen BK, Feinberg MB, Baltimore D. 1997. The B sites in the human immunodeficiency virus type 1 long terminal repeat enhance virus replication yet are not absolutely required for viral growth. J. Virol. 71:5495-504
3. Lassen KG, Bailey JR, Siliciano RF. 2004. Analysis of human immunodeficiency virus type 1 transcriptional elongation in resting CD4+ T cells in vivo. J. Virol. 78:9105-14
4. Feinberg MB, Baltimore D, Frankel AD. 1991. The role of Tat in the human immunodeficiency virus life cycle indicates a primary effect on transcriptional elongation. PNAS 88:4045-49
5. Berkhout B, Silverman RH, Jeang KT. 1989. Tat trans-activates the human immunodeficiency virus through a nascent RNA target. Cell 59:273-82
6. Wei P, Garber ME, Fang SM, Fischer WH, Jones KA. 1998. A novel CDK9-associated c-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell 92:451-62
7. Rahl PB, Lin CY, Seila AC, Flynn RA, McCuine S, et al. 2010. c-Myc regulates transcriptional pause release. Cell 141:432-45
8. Peterlin BM, Price DH. 2006. Controlling the elongation phase of transcription with P-TEFb. Mol. Cell 23:297-305
9. Garber ME,Wei P, KewalRamani VN, Mayall TP,Herrmann CH, et al. 1998. The interaction between HIV-1 Tat and human cyclin T1 requires zinc and a critical cysteine residue that is not conserved in the murine CycT1 protein. Genes Dev. 12:3512-27
10. Nguyen VT, Kiss T, Michels AA, Bensaude O. 2001. 7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes. Nature 414:322-25
11. Yang Z, ZhuQ, Luo K, Zhou Q. 2001. The 7SK small nuclear RNA inhibits the CDK9/cyclin T1 kinase to control transcription. Nature 414:317-22
12. Michels AA, Fraldi A, Li Q, Adamson TE, Bonnet F, et al. 2004. Binding of the 7SK snRNA turns the HEXIM1 protein into a P-TEFb (CDK9/cyclin T) inhibitor. EMBO J. 23:2608-19
13. Sedore SC, Byers SA, Biglione S, Price JP,Maury WJ, Price DH. 2007. Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic Acids Res. 35:4347-58
14. Barboric M, Yik JHN, Czudnochowski N, Yang Z, Chen R, et al. 2007. Tat competes with HEXIM1 to increase the active pool of P-TEFb for HIV-1 transcription. Nucleic Acids Res. 35:2003-12
15. D'Orso I, Frankel AD. 2010. RNA-mediated displacement of an inhibitory snRNP complex activates transcription elongation. Nat. Struct. Mol. Biol. 17:815-21
16. Sobhian B, Laguette N, Yatim A, Nakamura M, Levy Y, et al. 2010. HIV-1 Tat assembles a multifunctional transcription elongation complex and stably associates with the 7SK snRNP. Mol. Cell 38:439-51
17. He N, Liu M, Hsu J, Xue Y, Chou S, et al. 2010. HIV-1 Tat and host AFF4 recruit two transcription elongation factors into a bifunctional complex for coordinated activation of HIV-1 transcription. Mol. Cell 38:428-38
18. Lu H, Li Z, Xue Y, Schulze-Gahmen U, Johnson JR, et al. 2014. AFF1 is a ubiquitous P-TEFb partner to enable Tat extraction of P-TEFb from 7SK snRNP and formation of SECs for HIV transactivation. PNAS 111:E15-24
19. Schulze-Gahmen U, Lu H, Zhou Q, Alber T. 2014. AFF4 binding to Tat-P-TEFb indirectly stimulates TAR recognition of super elongation complexes at the HIV promoter. eLife 2014:1-13
20. Izmailova E, Bertley FM, Huang Q,Makori N,Miller CJ, et al. 2003. HIV-1 Tat reprograms immature dendritic cells to express chemoattractants for activated T cells and macrophages. Nat. Med. 9:191-97
21. Frankel AD, Pabo CO. 1988. Cellular uptake of the Tat protein from human immunodeficiency virus. Cell 55:1189-93
22. Rayne F, Debaisieux S, Yezid H, Lin Y-L, Mettling C, et al. 2010. Phosphatidylinositol-(4,5)-bisphosphate enables efficient secretion of HIV-1 Tat by infected T-cells. EMBO J. 29:1348-62
23. Kim N, Kukkonen S, Gupta S, Aldovini A. 2010. Association of Tat with promoters of PTEN and PP2A subunits is key to transcriptional activation of apoptotic pathways in HIV-infected CD4+ T cells. PLOS Pathog. 6:e1001103
24. Reeder JE, Kwak YT,McNamara RP, Forst CV, D'Orso I. 2015. HIV Tat controls RNA polymerase II and the epigenetic landscape to transcriptionally reprogram target immune cells. eLife 4:1-44
25. Tahirov TH, Babayeva ND, Varzavand K, Cooper JJ, Sedore SC, Price DH. 2010. Crystal structure of HIV-1 Tat complexed with human P-TEFb. Nature 465:747-51
26. Yang Z, Yik JHN, Chen R, He N, Moon KJ, et al. 2005. Recruitment of P-TEFb for stimulation of transcriptional elongation by the bromodomain protein Brd4. Mol. Cell 19:535-45
27. Kanazawa S, Okamoto T, Peterlin BM. 2000. Tat competes with CIITA for the binding to P-TEFb and blocks the expression of MHC class II genes in HIV infection. Immunity 12:61-70
28. Li Z, Guo J,Wu Y, ZhouQ. 2013. The BET bromodomain inhibitor JQ1 activates HIV latency through antagonizing Brd4 inhibition of Tat-transactivation. Nucleic Acids Res. 41:277-87
29. Mann DA, Frankel AD. 1991. Endocytosis and targeting of exogenous HIV-1 Tat protein. EMBO J. 10:1733-39
30. Johnson TP,Patel K, Johnson KR,Maric D, Calabresi PA, et al. 2013. Induction of IL-17 and nonclassical T-cell activation by HIV-Tat protein. PNAS 110:13588-93
31. Li CJ, Ueda Y, Shi B, Borodyansky L, Huang L, et al. 1997. Tat protein induces self-perpetuating permissivity for productive HIV-1 infection. PNAS 94:8116-20
32. Fernandes J, Faust TB, Frankel AD. 2016. Functional segregation of overlapping genes in HIV. Cell 167:1762-66.e12
33. Pollard VW, Malim MH. 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52:491-532
34. Malim MH, Hauber J, Le SY, Maizel JV, Cullen BR. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-57
35. Bai Y, Tambe A, Zhou K, Doudna JA. 2014. RNA-guided assembly of Rev-RRE nuclear export complexes. eLife 3:e03656
36. DaughertyMD, BoothDS, Jayaraman B,Cheng Y, Frankel AD. 2010. HIV Rev response element (RRE) directs assembly of the Rev homooligomer into discrete asymmetric complexes. PNAS 107:12481-86
37. Jayaraman B, Crosby DC, Homer C, Ribeiro I, Mavor D, Frankel AD. 2014. RNA-directed remodeling of theHIV-1 proteinRev orchestrates assembly of theRev-Rev response element complex. eLife 3:e04120
38. Pond SJK, Ridgeway WK, Robertson R, Wang J, Millar DP. 2009. HIV-1 Rev protein assembles on viral RNA one molecule at a time. PNAS 106:1404-8
39. Rausch JW, le Grice SFJ. 2015. HIV Rev assembly on the Rev response element (RRE): a structural perspective. Viruses 7:3053-75
40. Fornerod M, Ohno M, YoshidaM,Mattaj IW. 1997.CRM1is an export receptor for leucine-rich nuclear export signals. Cell 90:1051-60
41. Booth DS, Cheng Y, Frankel AD. 2014. The export receptor CRM1 forms a dimer to promote nuclear export of HIV RNA. eLife 3:e04121
42. Felber BK, Drysdale CM, Pavlakis GN. 1990. Feedback regulation of human immunodeficiency virus type 1 expression by the Rev protein. J. Virol. 64:3734-41
43. Lata S, Ali A, Sood V, Raja R, Banerjea AC. 2015. HIV-1 Rev downregulates Tat expression and viral replication via modulation of NAD(P)H:quinine oxidoreductase 1 (nqo1). Nat. Commun. 6:7244
44. Asher G, Tsvetkov P, Kahana C. 2005. A mechanism of ubiquitin-independent proteasomal degradation of the tumor suppressors p53 and p73. Genes Dev. 19:316-21
45. Larue RS, Lengyel J, Jonsson SR, Andrésdottir V, Harris RS. 2010. Lentiviral Vif degrades the APOBEC3Z3/APOBEC3H protein of its mammalian host and is capable of cross-species activity. J. Virol. 84:8193-201
46. Sheehy AM, Gaddis NC, Choi JD, Malim MH. 2002. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 418:646-50
47. Harris RS, Bishop KN, Sheehy AM, Craig HM, Petersen-Mahrt SK, et al. 2003. DNA deamination mediates innate immunity to retroviral infection. Cell 113:803-9
48. Yu X, Yu Y, Liu B,Luo K, KongW,et al. 2003. Induction ofAPOBEC3Gubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 302:1056-60
49. Sheehy AM, Gaddis NC, Malim MH. 2003. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nat. Med. 9:1404-7
50. Jäger S, Kim DY, Hultquist JF, Shindo K, LaRue RS, et al. 2011. Vif hijacks CBF-to degrade APOBEC3G and promote HIV-1 infection. Nature 481:371-75
51. Zhang W, Du J, Evans SL, Yu Y, Yu X-F. 2012. T-cell differentiation factor CBF-regulates HIV-1 Vif-mediated evasion of host restriction. Nature 481:376-69
52. Guo Y, Dong L, Qiu X, Wang Y, Zhang B, et al. 2014. Structural basis for hijacking CBF-and CUL5 E3 ligase complex by HIV-1 Vif. Nature 505:229-33
53. Hultquist JF, Binka M, LaRueRS, SimonV,HarrisRS. 2012. Vif proteins of human and simian immunodeficiency viruses require cellular CBFB to degrade APOBEC3 restriction factors. J. Virol. 86:2874-77
54. Kim DY, Kwon E, Hartley PD, Crosby DC,Mann S, et al. 2013. CBF stabilizesHIV Vif to counteract APOBEC3 at the expense of RUNX1 target gene expression. Mol. Cell 49:632-44
55. Miyagi E, Kao S, Yedavalli V, Strebel K. 2014. CBF enhances de novo protein biosynthesis of its binding partners HIV-1 Vif and RUNX1 and potentiates the Vif-induced degradation of APOBEC3G. J. Virol. 88:4839-52
56. Kane JR, Stanley DJ, Hultquist JF, Johnson JR,Mietrach N, et al. 2015. Lineage-specific viral hijacking of non-canonical E3 ubiquitin ligase cofactors in the evolution of Vif anti-APOBEC3 activity. Cell Rep. 11:1236-50
57. Salter JD, Morales GA, Smith HC. 2014. Structural insights for HIV-1 therapeutic strategies targeting Vif. Trends Biochem. Sci. 39:373-80
58. Rose KM, Marin M, Kozak SL, Kabat D. 2004. The viral infectivity factor (Vif ) of HIV-1 unveiled. Trends Mol. Med. 10:291-97
59. Harris RS, Liddament MT. 2004. Retroviral restriction by APOBECproteins. Nat. Rev. Immunol. 4:868-77
60. Hultquist JF, Harris RS. 2009. Leveraging APOBEC3 proteins to alter the HIV mutation rate and combat AIDS. Future Virol. 4:605
61. Huang G, Shigesada K, Ito K,Wee HJ, Yokomizo T, et al. 2001. Dimerization with PEBP2 protects RUNX1/AML1 from ubiquitin-proteasome-mediated degradation. EMBO J. 20:723-33
62. Tahirov TH, Inoue-Bungo T, Morii H, Fujikawa A, Sasaki M, et al. 2001. Structural analyses of DNA recognition by the AML1/Runx-1 Runt domain and its allosteric control by CBF?. Cell 104:755-67
63. Klase Z, Yedavalli VS, Houzet L, Perkins M, Maldarelli F, et al. 2014. Activation of HIV-1 from latent infection via synergy of RUNX1 inhibitor Ro5-3335 and SAHA. PLOS Pathog. 10:e1003997
64. Anderson BD, Harris RS. 2015. Transcriptional regulation of APOBEC3 antiviral immunity through the CBF-/RUNX axis. Sci. Adv. 1:e1500296
65. Hultquist JF,McDougle RM, Anderson BD, Harris RS. 2012. HIV type 1 viral infectivity factor and the RUNX transcription factors interact with core binding factor on genetically distinct surfaces. AIDS Res. Hum. Retrovir. 28:1543-51
66. Greenwood EJ, Matheson NJ,Wals K, van den Boomen DJ, Antrobus R, et al. 2016. Temporal proteomic analysis of HIV infection reveals remodelling of the host phosphoproteome by lentiviral Vif variants. eLife p5:e18296
67. Strebel K, Klimkait T, Martin M. 1988. A novel gene of HIV-1, Vpu, and its 16-kilodalton product. Science 241:1221-23
68. Cohen EA, Terwilliger EF, Sodroski JG, Haseltine WA. 1988. Identification of a protein encoded by the vpu gene of HIV-1. Nature 334:532-34
69. Malim MH, Emerman M, An P, Duggal P,Wang LH, et al. 2008. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host Microbe 3:388-98
70. Matsuda Z, Chou M-J, Matsuda M, Huang J-H, Chen Y-M, et al. 1988. Human immunodeficiency virus type 1 has an additional coding sequence in the central region of the genome. PNAS 85:6968-72
71. Terwilliger EF, Cohen EA, Lu Y, Sodroski JG, HaseltineWA. 1989. Functional role of human immunodeficiency virus type 1 vpu. Microbiology 86:5163-67
72. Neil SJ, Zang T, Bieniasz PD. 2008. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-30
73. Van Damme N, Goff D, Katsura C, Jorgenson RL, Mitchell R, et al. 2008. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-52
74. Willey RL, Maldarelli F, Martin MA, Strebel K. 1992. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J. Virol. 66:7193-200
75. Ewart GD, Sutherland T, Gage PW, Cox GB, Curtin J. 1996. The Vpu protein of human immunodeficiency virus type 1 forms cation-selective ion channels. J. Virol. 70:7108-15
76. Schubert U, Ferrer-Montiel AV, Oblatt-Montal M, Henklein P, Strebel K,MontalM. 1996. Identification of an ion channel activity of the Vpu transmembrane domain and its involvement in the regulation of virus release from HIV-1-infected cells. FEBS Lett. 398:12-18
77. Kerkau T, Bacik I, Bennink JR, Yewdell JW, Húnig T, et al. 1997. The human immunodeficiency virus type 1 (HIV-1) Vpu protein interferes with an early step in the biosynthesis of major histocompatibility complex (MHC) class I molecules. J. Exp. Med. 185:1295-305
78. Akari H, Bour S, Kao S, Adachi A, Strebel K. 2001. The human immunodeficiency virus type 1 accessory protein Vpu induces apoptosis by suppressing the nuclear factor B-dependent expression of antiapoptotic factors. J. Exp. Med. 194:1299-312
79. Roy N, Pacini G, Berlioz-Torrent C, Janvier K. 2014. Mechanisms underlying HIV-1 Vpu-mediated viral egress. Front. Microbiol. 5:177
80. Margottin F, Bour SP, Durand H, Selig L, Benichou S, et al. 1998. A novel human WD protein, h-TrCP, that interacts with HIV-1 Vpu connects CD4 to the ER degradation pathway through an F-box motif. Mol. Cell 1:565-74
81. Magadán JG, Pérez-Victoria FJ, Sougrat R, Ye Y, Strebel K, et al. 2010. Multilayered mechanism of CD4 downregulation by HIV-1 Vpu involving distinct ER retention and ERAD targeting steps. PLOS Pathog. 6:e1000869
82. Magadán JG, Bonifacino JS. 2012. Transmembrane domain determinants of CD4 downregulation by HIV-1 Vpu. J. Virol. 86:757-72
83. Kupzig S, Korolchuk V, Rollason R, Sugden A, Wilde A, Banting G. 2003. Bst-2/HM1.24 is a RAFTassociated apical membrane protein with an unusual topology. Traffic 4:694-709
84. Perez-Caballero D, Zang T, Ebrahimi A, McNatt MW, Gregory DA, et al. 2009. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511
85. Goffinet C, Allespach I, Homann S, Tervo H-M, Habermann A, et al. 2009. HIV-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-97
86. Iwabu Y, Fujita H, Kinomoto M, Kaneko K, Ishizaka Y, et al. 2009. HIV-1 accessory protein Vpu internalizes cell-surface Bst-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 284:35060-72
87. Mangeat B, Gers-Huber G, Lehmann M, Zufferey M, Luban J, et al. 2009. HIV-1 Vpu neutralizes the antiviral factor tetherin/Bst-2 by binding it and directing its TrCP2-dependent degradation. PLOS Pathog. 5:e1000574
88. Douglas JL, Viswanathan K, McCarrollMN,Gustin JK, Früh K, Moses AV. 2009. Vpu directs the degradation of the human immunodeficiency virus restriction factor Bst-2/tetherin via a TrCP-dependent mechanism. J. Virol. 83:7931-47
89. Abada P, Noble B, Cannon PM. 2005. Functional domains within the human immunodeficiency virus type 2 envelope protein required to enhance virus production. J. Virol. 79:3627-38
90. Bour S, StrebelK. 1996.The human immunodeficiency virus (HIV) type 2 envelope protein is a functional complement to HIV type 1 Vpu that enhances particle release of heterologous retroviruses. J. Virol. 70:8285-300
91. Hauser H, Lopez LA, Yang SJ, Oldenburg JE, Exline CM, et al. 2010. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 7:51
92. Jia B, Serra-Moreno R, Neidermyer W, Rahmberg A, Mackey J, et al. 2009. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLOS Pathog. 5:e1000429
93. Le Tortorec A, Neil SJD. 2009. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 83:11966-78
94. Sauter D, Schindler M, Specht A, Landford WN, Münch J, et al. 2009. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell HostMicrobe 6:409-21
95. Yang SJ, Lopez LA, Hauser H, Exline CM, Haworth KG, Cannon PM. 2010. Anti-tetherin activities in Vpu-expressing primate lentiviruses. Retrovirology 7:13
96. Zhang F, Wilson SJ, Landford WC, Virgen B, Gregory D, et al. 2009. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 6:54-67
97. Matsuda A, Suzuki Y, Honda G, Muramatsu S, Matsuzaki O, et al. 2003. Large-scale identification and characterization of human genes that activateNF-B and MAPK signaling pathways. Oncogene 22:3307-18
98. Tokarev A, SuarezM, KwanW, Fitzpatrick K, Singh R, Guatelli J. 2013. Stimulation of NF-B activity by the HIV restriction factor BST2. J. Virol. 87:2046-57
99. Galão RP, Le Tortorec A, Pickering S, Kueck T, Neil SJD. 2012. Innate sensing of HIV-1 assembly by tetherin induces NF-B-dependent proinflammatory responses. Cell Host Microbe 12:633-44
100. Bour S, Perrin C, Akari H, Strebel K. 2001. The human immunodeficiency virus type 1 Vpu protein inhibits NF-B activation by interfering with TrCP-mediated degradation of IB. J. Biol. Chem. 276:15920-28
101. Besnard-Guerin C, Belädouni N, Lassot I, Segeral E, Jobart A, et al. 2004. HIV-1 Vpu sequesters transducin repeat-containing protein (TrCP) in the cytoplasm and provokes the accumulation of catenin and other SCFTrCP substrates. J. Biol. Chem. 279:788-95
102. Sauter D, Hotter D, Van Driessche B, Stürzel CM, Kluge SF, et al. 2015. Differential regulation of NF-kB-mediated proviral and antiviral host gene expression by primate lentiviral Nef and Vpu proteins. Cell Rep. 10:586-600
103. Manganaro L, de Castro E, Maestre AM, Olivieri K, Garca-Sastre A, et al. 2015. HIV Vpu interferes with NF-B activity but not with interferon regulatory factor 3. J. Virol. 89:9781-90
104. Hayden MS, Ghosh S, Hayden MS, Ghosh S. 2012. NF-kB, the first quarter-century: remarkable progress and outstanding questions. Genes Dev. 26:203-34
105. Kondo E, Mammano F, Cohen EA, Göttlinger HG. 1995. The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles. J. Virol. 69:2759-64
106. Andersen JL, Planelles V. 2005. The role of Vpr in HIV-1 pathogenesis. Curr. HIV Res. 3:43-51
107. LaiM, Zimmerman ES, Planelles V, Chen J. 2005. Activation of the ATR pathway by human immunodeficiency virus type 1 Vpr involves its direct binding to chromatin in vivo. J. Virol. 79:15443-51
108. Roshal M, Kim B, Zhu Y, Nghiem P, Planelles V. 2003. Activation of the ATR-mediated DNA damage response by the HIV-1 viral protein R. J. Biol. Chem. 278:25879-86
109. Zimmerman ES, Sherman MP, Blackett JL, Neidleman JA, Kreis C, et al. 2006. Human immunodeficiency virus type 1 Vpr induces DNA replication stress in vitro and in vivo. J. Virol. 80:10407-18
110. Belzile JP,Abrahamyan LG,GerardFCA,RougeauN,Cohen EA. 2010. Formation ofmobile chromatinassociated nuclear foci containing HIV-1 Vpr and VPRBP is critical for the induction of G2 cell cycle arrest. PLOS Pathog. 6:e1001080
111. Zimmerman ES, Chen J, Andersen JL, Ardon O, Dehart JL, et al. 2004. Human immunodeficiency virus type 1 Vpr-mediatedG2 arrest requires Rad17 andHus1 and induces nuclear BRCA1 andH2AX focus formation. Mol. Cell. Biol. 24:9286-94
112. Planelles V, Jowett JBM, Li Q-X, Xie Y, Hahn B, Chen ISY. 1996. Vpr-induced cell cycle arrest is conserved among primate lentiviruses. J. Virol. 70:2516-24
113. HreckaK,Gierszewska M, Srivastava S, Kozaczkiewicz L, Swanson SK, et al. 2007. Lentiviral Vpr usurps Cul4-DDB1[VPRBP] E3 ubiquitin ligase to modulate cell cycle. PNAS 104:11778-83
114. Belzile JP, Duisit G, Rougeau N, Mercier J, Finzi A, Cohen EA. 2007. HIV-1 Vpr-mediated G2 arrest involves the DDB1-CUL4AVPRBP E3 ubiquitin ligase. PLOS Pathog. 3:0882-93
115. Schröfelbauer B, Hakata Y, Landau NR. 2007. HIV-1 Vpr function is mediated by interaction with the damage-specific DNA-binding protein DDB1. PNAS 104:4130-35
116. Laguette N, Brégnard C, Hue P, Basbous J, Yatim A, et al. 2014. Premature activation of the SLX4 complex by Vpr promotes G2/M arrest and escape from innate immune sensing. Cell 156:134-45
117. Fregoso OI, Emerman M. 2016. Activation of the DNA damage response is a conserved function of HIV-1 and HIV-2 Vpr that is independent of SLX4 recruitment. mBio 7:1-10
118. Lovejoy CA, Lock K, Yenamandra A, Cortez D. 2006. DDB1 maintains genome integrity through regulation of Cdt1. Mol. Cell. Biol. 26:7977-90
119. Wu Y, Zhou X, Barnes CO, DeLucia M, Cohen AE, et al. 2016. The DDB1-DCAF1-Vpr-UNG2 crystal structure reveals how HIV-1 Vpr steers human UNG2 toward destruction. Nat. Struct. Mol. Biol. 23:933-40
120. Chen R, Le Rouzic E, Kearney JA, Mansky LM, Benichou S. 2004. Vpr-mediated incorporation of UNG2 into HIV-1 particles is required to modulate the virus mutation rate and for replication in macrophages. J. Biol. Chem. 279:28419-25
121. Wang L, Mukherjee S, Jia F, Narayan O, Zhao LJ. 1995. Interaction of virion protein Vpr of human immunodeficiency virus type 1 with cellular transcription factor Sp1 and trans-activation of viral long terminal repeat. J. Biol. Chem. 270:25564-69
122. Sawaya BE, Khalili K, Gordon J, Taube R, Amini S. 2000. Cooperative interaction between HIV-1 regulatory proteins Tat and Vpr modulates transcription of the viral genome. J. Biol. Chem. 275:35209-14
123. Gummuluru S, Emerman M. 1999. Cell cycle-and Vpr-mediated regulation of human immunodeficiency virus type 1 expression in primary and transformed T-cell lines. J. Virol. 73:5422-30
124. GohWC, RogelME, KinseyCM,Michael SF, FultzPN, et al. 1998. HIV-1Vpr increases viral expression by manipulation of the cell cycle: a mechanism for selection of Vpr in vivo. Nat. Med. 4:65-71
125. Forget J, Yao XJ, Mercier J, Cohen EA. 1998. Human immunodeficiency virus type 1 Vpr protein transactivation function: mechanism and identification of domains involved. J. Mol. Biol. 284:915-23
126. Felzien LK, WoffendinC,HottigerMO, Subbramanian RA,Cohen EA, Nabel GJ. 1998. HIV transcriptional activation by the accessory protein, Vpr, is mediated by the p300 co-activator. PNAS 95:5281-86
127. Zahoor MA, Xue G, Sato H, Murakami T, Takeshima SN, Aida Y. 2014. HIV-1 Vpr induces interferonstimulated genes in human monocyte-derived macrophages. PLOS ONE 9:e106418
128. Campbell MJ, Cho RJ, Huang M, Dong H, Steinmetz L, et al. 2001. Transcriptional regulation and function during the human cell cycle. Nat. Genet. 27:48-54
129. Allan J, Coligan J, Lee T, McLane M, Kanki P, et al. 1985. A new HTLV-III/LAV encoded antigen detected by antibodies from AIDS patients. Science 230:810-13
130. Kirchhoff F, Greenough TC, Brettler DB, Sullivan JL, Desrosiers RC. 1995. Absence of intact Nef sequences in a long-term survivor with nonprogressive HIV-1 infection. N. Engl. J. Med. 332:228-32
131. Guy B, Kieny MP, Riviere Y, Le Peuch C, Dott K, et al. 1987. HIV F/3- ORF encodes a phosphorylated GTP-binding protein resembling an oncogene product. Nature 330:266-69
132. Garcia JV, Miller AD. 1991. Serine phosphorylation-independent downregulation of cell-surface CD4 by Nef. Nature 350:508-11
133. Schaefer MR, Wonderlich ER, Roeth JF, Leonard JA, Collins KL. 2008. HIV-1 Nef targets MHC-I and CD4 for degradation via a final common COP-dependent pathway in T cells. PLOS Pathog. 4:e1000131
134. Schwartz O, Maréchal V, Le Gall S, Lemonnier F, Heard J-M. 1996. Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat. Med. 2:338-42
135. Stumptner-Cuvelette P, Morchoisne S, Dugast M, Le Gall S, Raposo G, et al. 2001. HIV-1 Nef impairs MHC class II antigen presentation and surface expression. PNAS 98:12144-49
136. Geyer M, Fackler OT, Peterlin BM. 2001. Structure-function relationships in HIV-1 Nef. EMBO Rep. 2:580-85
137. Roeth JF, WilliamsM, KasperMR, FilzenTM, CollinsKL. 2004. HIV-1Nef disruptsMHC-I trafficking by recruiting AP-1 to the MHC-I cytoplasmic tail. J. Cell Biol. 167:903-13
138. Chaudhuri R, Lindwasser OW, Smith WJ, Hurley JH, Bonifacino JS. 2007. Downregulation of CD4 by human immunodeficiency virus type 1 Nef is dependent on clathrin and involves direct interaction of Nef with the ap2 clathrin adaptor. J. Virol. 81:3877-90
139. Wildum S, SchindlerM,Münch J, Kirchhoff F. 2006. Contribution of Vpu, Env, andNef to CD4 downmodulation and resistance of human immunodeficiency virus type 1-infected T cells to superinfection. J. Virol. 80:8047-59
140. Usami Y, Wu Y, Göttlinger HG. 2015. SERINC3 and SERINC5 restrict HIV-1 infectivity and are counteracted by Nef. Nature 526:218-23
141. Rosa A, Chande A, Ziglio S, De Sanctis V, Bertorelli R, et al. 2015. HIV-1 Nef promotes infection by excluding SERINC5 from virion incorporation. Nature 526:212-17
142. Wang J-K, Kiyokawa E, Verdin ETD. 2000. The Nef protein of HIV-1 associates with rafts and primes T cells for activation. PNAS 72:1337-40
143. Mangino G, Percario ZA, Fiorucci G, Vaccari G, Acconcia F, et al. 2011. HIV-1 Nef induces proinflammatory state in macrophages through its acidic cluster domain: involvement of TNF alpha receptor associated factor 2. PLOS ONE 6:e22982
144. Sauter D, Hotter D, Van Driessche B, Stürzel CM, Kluge SF, et al. 2015. Differential regulation of NF-B-mediated proviral and antiviral host gene expression by primate lentiviralNef and Vpu proteins. Cell Rep. 10:586-99
145. Williams SA, Chen L-F, Kwon H, Ruiz-Jarabo CM, Verdin E,GreeneWC. 2006. NF-B p50 promotes HIV latency through HDAC recruitment and repression of transcriptional initiation. EMBO J. 25:139-49
146. Simmons A, Aluvihare V,McMichael A. 2001. Nef triggers a transcriptional program in Tcells imitating single-signal T cell activation and inducing HIV virulence mediators. Immunity 14:763-77
147. Querido E, Morrison MR, Chu-Pham-Dang H, Thirlwell SW, Boivin D, et al. 2001. Identification of three functions of the adenovirus E4orf6 protein that mediate p53 degradation by the E4orf6-E1B55K complex. J. Virol. 75:699-709
148. ScheffnerM,Werness BA, Huibregtse JM, Levine AJ, Howley PM. 1990. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63:1129-36
149. Edwards MR, Johnson B, Mire CE, XuW, Shabman RS, et al. 2014. The Marburg virus VP24 protein interacts with Keap1 to activate the cytoprotective antioxidant response pathway. Cell Rep. 6:1017-25
150. Felsani A,Mileo AM, Paggi MG. 2006. Retinoblastoma family proteins as key targets of the small DNA virus oncoproteins. Oncogene 25:5277-85
151. Pavletich NP, Lee J-O, Russo AA. 1998. Structure of the retinoblastoma tumour-suppressor pocket domain bound to a peptide from HPV E7. Nature 391:859-65
152. Iaquinta PJ, Lees JA. 2007. Life and death decisions by the E2F transcription factors. Curr. Opin. Cell Biol. 19:649-57